

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 16, 2011**

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation)	000-21846 (Commission File Number)	13-3632859 (I.R.S. Employer Identification No.)
8910 University Center Lane, Suite 660 San Diego, California (Address of principal executive offices)		92122 (Zip Code)

Registrant's telephone number, including area code: **(858) 459-7800**

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01 Regulation FD Disclosure

The Registrant disclosed that on Thursday, June 16, 2011, it made a presentation at the LHA Life Sciences & Medical Technology Virtual Conference. A copy of the presentation materials is being furnished as an exhibit to this report and is incorporated by reference into this Item 7.01. Also, the Registrant posted the presentation materials to its website (www.aethlonmedical.com) today, June 16, 2011.

The Registrant notes that the following points made in the presentation were disclosures that may represent new information:

Slide number 5 - The registrant detailed the Aethlon ADAPT(™) system.

Slide number 11 – The Registrant has initiated a research study to test the ability of the Aethlon Hemopurifier® to capture of HIV related exosomes that transport immunosuppressive NEF protein.

Slide number 29 – The Registrant detailed its government contract and grant submissions.

The Registrant disclosed that it submitted a response to BARDA CBRN BAA-11-100-00009 on May 31, 2011

The Registrant disclosed plans to submit a proposal to U.S. Army, Blood Purification for Organ Failure SBIR by June 29, 2011

Slide number 30 - The registrant disclosed that its wholly owned subsidiary Exosome Sciences, Inc. may license or initiate sales of the ELLSA research diagnostic tools that identify and quantify exosomes. Registrant disclosed that over 70% of researchers polled in market survey indicated interest in purchasing the product.

Slide number 31 – The Registrant provided an update on Hepatitis C clinical studies being conducted at the Medanta-Medicity Institute in Delhi, India.

Slide number 33 – Registrant disclosed clinical program opportunities in the European Union; that it is reviewing an investigator-driven protocol proposal to treat cancer patients on dialysis; and plans to request permission from FDA to initiate U.S. clinical studies.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is being furnished pursuant to Item 7.01 above.

Exhibit No.	Description
99.1	LHA Life Sciences & Medical Technology Virtual Conference Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.
(Registrant)

Date: June 16, 2011

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation Materials



LHA Life Sciences & Medical Technology
Virtual Conference

June 16, 2011

Jim Joyce
Chairman, CEO

OTCBB:AEMD



Forward Looking Statements

This presentation contains predictions, estimates and other forward-looking statements that involve risks and uncertainties, including whether and when our Aethlon ADAPT™ System, Hemopurifier® and other product offerings are successfully developed and introduced, market acceptance of our Aethlon ADAPT™ System, Hemopurifier® and other product offerings, regulatory delays, manufacturing delays and other risks detailed in our filings with the Securities and Exchange Commission (SEC) accessible online at www.sec.gov or www.aethlonmedical.com

Our mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions



Investment Highlights

- Adaptable Therapeutic Filtration Device Platform
- Our Products Address Unmet Medical Needs
- Our Products Address Large Markets
- Early Adopter Distribution Channel in Place
- 4 Paths To Early Revenue
- New Clinical Programs



The Aethlon ADAPT™ System

Adaptive Dialysis-like Affinity Platform Technology

- Converges proven plasma membrane technology with antibodies or other affinity drug agents
- Provides foundation for an expansive pipeline of selective therapeutic filtration (STF) devices
- Transforms drug agent mechanism from biologic to less burdensome medical device regulatory pathway
- Repurposes development-stage, clinical-stage, branded, and clinical dropout affinity drugs



The Adapt™ System Pipeline

Introduced to the drug industry on May 25th, 2011

- The Aethlon Hemopurifier®
- STF device to reduce incidence of sepsis
 - Proposed in DARPA Dialysis-Like Therapeutics contract response
- STF device to address trauma related organ failure
 - To be proposed in forthcoming U.S. Army response

Denotes new disclosure





The Hemopurifier®

The first medical device to selectively remove infectious viruses and immunosuppressive particles from circulation

The Hemopurifier®

A Broad-Spectrum Therapeutic Device

- Hepatitis C
- HIV
- Cancer
- Bioterror & Pandemic Threats



Investment Highlight

The Hemopurifier® Addresses
Unmet Medical Needs



Bioterror & Pandemic Threats

Unmet Medical Need Targeted by the Aethlon Hemopurifier®


- Fulfills the HHS broad-spectrum treatment mandate
- Solution for emerging or released pathogens not addressed by drugs or vaccines
- Solution for genetically modified or synthetically engineered pathogens



Human Immunodeficiency Virus (HIV)

Unmet Medical Need Targeted by the Aethlon Hemopurifier®

- A solution to drug resistance
- Removes all viral strains
- Captures immunosuppressive gp120
- Research study has been initiated to test the capture of HIV-released exosomes that transport NEF protein




Denotes new disclosure



Hepatitis C Virus (HCV)

Unmet Medical Need Targeted by the Aethlon Hemopurifier®


- Addresses all genotypes
- Accelerates viral load depletion w/o drug toxicity and interaction risks
- Selective mechanism advances proven benefit of therapeutic filtration without removing essential blood components



Hepatitis C Virus (HCV)

Unmet Medical Need Targeted by the Aethlon Hemopurifier®


- Addresses all genotypes
- Accelerates viral load depletion w/o drug toxicity and interaction risks
- Selective mechanism advances proven benefit of therapeutic filtration without removing essential blood components



Cancer

Unmet Medical Need Targeted by the Aethlon Hemopurifier®

- The first therapeutic strategy to address exosomes released by cancer
 - Induce apoptosis
 - Disrupt T-cell signaling
 - Inhibit anti-cancer cytokine production
 - Angiogenesis
 - Metastasis



Question?

Does The Hemopurifier® Really Have
Broad-Spectrum Capabilities?




In Vitro Confirmations Against
Bioterror and Pandemic Threats

Virus	Collaborator
Ebola	USAMRIID/CDC
Dengue	NIV/WHO
Lassa	SFBR
West Nile	Battelle
H5N1 Avian	Battelle
1918-r Spanish Flu	Battelle
2009 H1N1 Swine	Battelle
Monkey Pox	Battelle


HIV-AIDS Study

- Infected dialysis patient
- 12 treatments / 30 days
- 4 hrs per treatment
- Performed in absence of drug therapy
- Average per treatment viral load reduction of 54%
- Improved CD4 t-cell ratios



Human HCV Studies

- Average per treatment viral load reduction of 64%
- Infected dialysis patients
- 4 hour treatments
- Performed in absence of drug therapy
- Calculated from 36 treatments



In vitro Cancer Exosome Validations

- Ovarian
- Breast
- Colorectal
- Lymphoma
- Melanoma



Investment Highlight


The Hemopurifier® Addresses
Large Market Disease Conditions



Size of Hemopurifier® Markets

Not Inclusive of Biodefense & Pandemic Opportunities


Over 200 Million Afflicted



\$ Value of Hemopurifier® Markets

Not Inclusive of Biodefense & Pandemic Opportunities

Annual Size of Therapeutic Market in \$BN



Investment Highlight

Early Adopter Distribution
Channel in Place



Hemopurifier® therapy can be delivered through the established global infrastructure of dialysis machines (90,000 in U.S. alone)



The Early Adopter Distribution Channel

- 20,000 Nephrologists who will know how to administer Hemopurifier® therapy
- Over 15,000 dialysis centers available to become official Hemopurifier® therapy locations
 - No additional infrastructure required
- 2 million dialysis patients already being treated by Nephrologists
 - Incidence of HCV is 100-1000x greater than general population
 - Dialysis patients also have higher incidences of Cancer and HIV
 - Hemopurifier® therapy can be administered during scheduled dialysis treatments





The Future

Home delivery of the Hemopurifier® and other devices evolved from the Aethlon ADAPT™ system



Investment Highlight

4 Paths to Early Revenue



4 Paths to Early Revenue

1. Aethlon ADAPT™ system revenues
2. Government Contract or Grant Income
3. Research Diagnostics
4. Hemopurifier® Commercialization



4 Paths to Early Revenue
1.) Aethlon ADAPT™ System Revenues

- Multi-channel revenue opportunity driven by future products created through drug industry collaborations
- Product development fees
- Fees from research, regulatory, and manufacturing support
- Downstream royalties



4 Paths to Early Revenue
2.) Government Contract or Grant Income

- Pending – Response to DARPA-BAA-11-30 entitled, "Dialysis-Like Therapeutics" submitted April 1, 2011
- Pending – Response to BARDA CBRN BAA-11-100-00009 submitted on May 31, 2011
- Forthcoming submission – U.S. Army, Blood Purification for Organ Failure SBIR due June 29th

Denotes new disclosure



4 Paths to Early Revenue
3.) Research Diagnostics



- Licensing or initial sales of our ELLSA research diagnostic tools that identify and quantify exosomes
- Over 70% of researchers polled in market survey indicated interest in purchasing the product

Denotes new disclosure



4 Paths to Early Revenue

4.) Hemopurifier® Commercialization

- A 30 patient study underway at the Medanta-Medicity Institute in Delhi, India
- Treatment target: HCV
- Primary study objective: To demonstrate Hemopurifier® therapy accelerates early viral load depletion when combined with HCV-SOC therapy
- Achievement of study objectives will trigger first commercialization in India
 - Status – 5 patients completed / patient 6 & 7 enrolled
 - Creating a drug subsidy program to accelerate enrollment

Denotes new disclosure



Investment Highlight

Expansion of Clinical Programs



Expansion of Clinical Programs

- Discussing clinical program opportunities in the EU with candidate collaborators and partners
- Reviewing an investigator-driven protocol related to the treatment of cancer patients on dialysis
- We plan to request permission from FDA to initiate U.S. clinical programs this summer
 - IDE on file related to treatment of bioterror and pandemic threats
 - We will also seek permission from FDA to expand label indication to include treatment of HCV

Denotes new disclosure



Investment Highlights

- Adaptable Therapeutic Filtration Device Platform
- Our Products Address Unmet Medical Needs
- Our Products Address Large Markets
- Early Adopter Distribution Channel in Place
- 4 Paths To Early Revenue
- New Clinical Programs



Presenter Information

Jim Joyce

Chairman, CEO

Aethlon Medical, Inc.

(858) 459-7800 x301

jj@aethlonmedical.com





8910 University Center Lane, Suite 660

San Diego, CA. 92122

www.AethlonMedical.com

